Boston University's Center for Global Health & Development (CGHD)’s work is driven by a deep commitment to use the power of science to promote social change and improve the health of populations worldwide. The CGHD’s faculty and professional staff currently manage more than 50 research projects and programs in over 20 countries. The Opti-Q study will determine the levofloxacin dose and exposure that achieve the greatest reduction in TB bacterial burden with acceptable tolerability by studying 100 adults with MDR-TB at sites in Peru and South Africa.

The National Institute of Allergy and Infectious Diseases (NIAID) conducts and supports basic and applied research to better understand, treat, and ultimately prevent infectious, immunologic, and allergic diseases. For more than 60 years, NIAID research has led to new therapies, vaccines, diagnostic tests, and other technologies that have improved the health of millions of people in the United States and around the world. NIAID is one of the 27 Institutes and Centers of the National Institutes of Health (NIH) within the U.S. Government's Department of Health and Human Services, .